Apellis Q3 revenue jumps to $459 mln with Sobi payment

Apellis Pharmaceuticals

30/10/2025 11:12

Overview

Apellis Q3 2025 revenue reached $459 mln, driven by product sales and Sobi payment

Net income for Q3 2025 was $215.7 mln, boosted by Sobi royalty payment

Company's cash position strong at $479 mln, expected to fund business to profitability

Outlook

Apellis expects current cash and revenues to fund operations to profitability

Company plans pivotal studies for EMPAVELI in rare kidney diseases by year-end 2025

Apellis anticipates EMA opinion on Aspaveli indication extension by year-end 2025

Result Drivers

EMPAVELI LAUNCH - Strong early launch of EMPAVELI for C3G and IC-MPGN with 152 new patient start forms received

SYFOVRE DEMAND - SYFOVRE injection demand grew 4% quarter-over-quarter, maintaining market leadership in geographic atrophy

SOBI PAYMENT - $275 mln upfront payment from Sobi for royalty purchase agreement significantly boosted revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$177.75 mln
Q3 EPS
$1.67
Q3 Net Income
$215.71 mln
Q3 Basic EPS
$1.71
Q3 Operating Expenses
$235.39 mln
Q3 Operating Income
$223.18 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $35.00, about 14.1% above its October 29 closing price of $30.05

Press Release: ID:nGNX3JrQZ6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)